Trial Profile
Identify and characterise diabetes towards limiting its progression.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Peptide p277 (Primary)
- Indications Latent autoimmune diabetes in adults
- Focus Registrational; Therapeutic Use
- Acronyms ACTION-LADA
- 06 Mar 2012 Planned end date changed from 1 Sep 2012 to 1 Mar 2012 as reported by UKCRN.
- 06 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
- 02 Oct 2011 Planned end date changed from 31 Dec 2010 to 1 Sep 2012 as reported by UKCRN.